|
AU2003218460A1
|
|
Compositions and methods for immunomodulation
|
|
WO03039487A2
|
|
Cyclo(prolyl-glycine) and methods of use to treat neural disorders
|
|
WO03000281A1
|
|
Neuroprotection and/or neurorestoration via the neural avtivin type iib receptor
|
|
AU2002303856A1
|
|
Gpe analogs and peptidomimetics
|
|
EP1377307A2
|
|
Anti-gpe antibodies, their uses, and analytical methods for gpe
|
|
US6682753B2
|
|
Methods for promoting weight gain using GPE-related compounds
|
|
WO03049761A1
|
|
Use of insuline-like growth factor-i for promoting remyelination of axons
|
|
AU3074902A
|
|
Functional proteomics using double phage display screening
|
|
AU1324002A
|
|
Treatment of demyelinating diseases
|
|
AU1284802A
|
|
Sensor assembly for monitoring an infant brain
|
|
AU8916001A
|
|
Gpe analogs
|
|
US6812208B2
|
|
Methods to improve neural outcome
|
|
EP1109572A2
|
|
Neuroprotection
|
|
NZ510253A
|
|
Neuroprotection
|
|
CN1305383A
|
|
Regulation of tyrosine bydroxylase
|
|
NZ335544A
|
|
Use of GPE (tripeptide or dipeptide) in form of Gly-Pro-Glu or Gly-Pro or Pro-Glu as a neuromodulator
|
